🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

6,931 results for “The” Clear

  1. Polyamide HD membrane

    Sionna Therapeutics

    End-stage Kidney Disease

    phase 3 other active

    1 trial

  2. Ponesimod

    Vanda Pharmaceuticals Netherlands B.V.

    Moderate-to-severe Chronic Plaque Psoriasis

    phase 3 small molecule active

    1 trial

  3. Pozelimab + Cemdisiran

    Regeneron UK Limited

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  4. Pravastatina Kern Pharma 40 mg comprimidos EFG, Placebo Pravastatina

    The George Institute

    intrauterine growth restriction, preeclampsia

    phase 3 small molecule active

    1 trial

  5. Prednisolone

    United Therapeutics Europe Ltd

    Adrenal Insufficiency

    phase 3 small molecule active

    1 trial

  6. Prednisolone 10mg Tablets, Avastin 25 mg/ml concentrate for solution for infusion., Sodium Chloride Fresenius Kabi Italia 0.9 % Solution for infusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Brain metastases of cancer > brain radionecrosis

    phase 3 small molecule active

    1 trial

  7. Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR

    The First People's Hospital of Lianyungang

    Colorectal Neoplasms

    phase 3 other active

    1 trial

  8. Privigen 100 mg/ml solution for infusion, Gammanorm, 165 mg/ml, oplossing voor injectie, Octagam 10%, oplossing voor infusie, Nanogam 100 mg/ml oplossing voor infusie, Hizentra 200 mg/ml solution for subcutaneous injection, HyQvia 100 mg/ml solution for infusion for subcutaneous use, Cuvitru 200 mg/ml oplossing voor subcutane injectie, KIOVIG 100 mg/ml solution for infusion, CUTAQUIG 165 mg/mL, solution injectable, GAMMAGARD S/D 5,0 g, poeder en oplosmiddel voor oplossing voor infusie.

    Disc Medicine

    Primary antibody deficiency: - Unclassified antibody deficiency (unPAD) - IgA deficiency - Specific polysaccharide antibody deficiency (SPAD) - IgG subclass deficiency (IgSD) - Common variable immunodeficiency (CVID) - Agammaglobulinemia (X-linked or otherwise)

    phase 3 small molecule active

    1 trial

  9. Progesterone

    TherapeuticsMD

    Secondary Amenorrhea

    phase 3 small molecule terminated

    1 trial

  10. Progesterone

    United Therapeutics Europe Ltd

    Alcohol Dependence

    phase 3 small molecule completed

    1 trial

  11. Propranolol

    United Therapeutics Europe Ltd

    Burn

    phase 3 small molecule terminated

    1 trial

  12. Psilocybin

    Compass Therapeutics

    Major Depressive Disorder

    phase 3 small molecule active

    2 trials

  13. Psilocybin

    Compass Therapeutics

    Treatment Resistant Depression

    phase 3 small molecule active

    7 trials

  14. QRX003

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    1 trial

  15. QRX003, 4% Lotion

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    2 trials

  16. QRX003-2% Lotion

    Quoin Pharmaceuticals,

    Netherton Syndrome

    phase 3 small molecule active

    1 trial

  17. QTORIN 3.9% Rapamycin Anhydrous Gel

    PALVELLA THERAPEUTICS, INC.

    Microcystic Lymphatic Malformation

    phase 3 small molecule active

    1 trial

  18. QTORIN 3.9% rapamycin anhydrous gel

    PALVELLA THERAPEUTICS, INC.

    Pachyonychia Congenita

    phase 3 small molecule completed

    1 trial

  19. QVM149

    Grace Therapeutics

    Asthma

    phase 3 small molecule terminated

    1 trial

  20. R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm

    Takeda

    Multiple Myeloma

    phase 3 small molecule active

    1 trial

  21. RAP-219

    Rapport Therapeutics

    Focal Seizure

    phase 3 small molecule active

    2 trials

  22. REL-1017

    RELMADA THERAPEUTICS, INC.

    Major Depressive Disorder

    phase 3 small molecule completed

    3 trials

  23. REN001

    OnKure Therapeutics

    Primary Mitochondrial Myopathy

    phase 3 small molecule terminated

    2 trials

  24. REOLYSIN

    ONCOLYTICS BIOTECH INC

    Carcinoma, Squamous Cell of the Head and Neck

    phase 3 mab completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources